Afatinib Dimaleate CAS 850140-73-7 Purity >99.5% (HPLC) API

Short Description:

Chemical Name: Afatinib Dimaleate

Synonyms: BIBW2992 Dimaleate

CAS: 850140-73-7

Purity: >99.0% (HPLC)  

Appearance: White to Off-White Powder 

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Afatinib Dimaleate 
Synonyms BIBW2992 Dimaleate;  (S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-Enamide Dimaleate 
CAS Number 618-89-3
CAT Number RF-PI2032
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C32H33ClFN5O11
Molecular Weight 718.08
Sensitivity Moisture Sensitive
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Powder
Purity / Analysis Method >99.5% (HPLC)
Loss on Drying <0.50%
Residue on Ignition <0.10%
Maximum Single Impurity <0.30%
Total Impurities <0.50%
Heavy Metals (as Pb) ≤20ppm
Infrared Spectrum Conforms to Structure
NMR  Conforms to Structure
Test Standard Enterprise Standard
Shelf Life 24 Months if Stored Properly
Usage API

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

Afatinib Dimaleate (CAS: 850140-73-7), the dimaleate salt form of afanitib, is an orally available antineoplastic agent. Afatinib Dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib Dimaleate is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. In the past, standard treatment with a platinum-based chemotherapy doublet regimen was considered standard first-line therapy for all patients with NSCLC. However, emerging evidence has identified subpopulations in which targeted therapy is more effective, leading to the development of mutation-specific drugs. Afatinib Dimaleate was Developed by Boehringer Ingelheim Pharmaceuticals, Afatinib Dimaleate was approved by the FDA in 2013 as an orphan drug under the trade name Gilotrif. Afatinib Dimaleate is chemically synthesized using standard methods. Afatinib Dimaleate is not only active against EGFR mutations targeted by first generation TKIs like erlotinib or gefitinib, but also against mutations such as T790M which are not sensitive to these standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers. 

  • Write your message here and send it to us